ADMA Biologics Q4 2023 Earnings Report
Key Takeaways
ADMA Biologics announced strong Q4 2023 results with a 48% increase in total revenues to $73.9 million compared to Q4 2022. The company reported an Adjusted EBITDA of $18.6 million for the quarter, a significant improvement from the Adjusted EBITDA loss of $3.5 million in the same period last year. The company's full year performance marked first-time positive adjusted net income.
Total revenues for Q4 2023 increased by 48% to $73.9 million.
Adjusted EBITDA for Q4 2023 was $18.6 million, compared to a loss of $3.5 million in Q4 2022.
Net loss for Q4 2023 was $17.6 million, compared to a net loss of $12.2 million in Q4 2022.
Adjusted net income for Q4 2023 was $8.5 million, compared to an Adjusted net loss of $12.2 million in Q4 2022.
ADMA Biologics
ADMA Biologics
Forward Guidance
ADMA Biologics increased financial guidance for 2024 and 2025.
Positive Outlook
- FY 2024 and 2025 total revenue now expected to be more than $330 million and $380 million, respectively, increased from prior guidance of $320 million and $370 million, respectively
- FY 2024 and 2025 net income now expected to exceed $65 million and $115 million, respectively, increased from prior guidance of $60 million and $110 million, respectively
- FY 2024 Adjusted EBITDA now anticipated to exceed $90 million, increased from $85 million previously
- FY 2025 Adjusted EBITDA expected to exceed $140 million
- Advancing new growth initiatives, including innovations to ADMA’s manufacturing processes and potential yield enhancement, as well as progress with our preclinical S. pneumonia pipeline program.
Challenges Ahead
- Biologic Production Yield Enhancement initiatives are subject to further evaluation, validation of commercial-scale production and requisite regulatory review.
- The increasing prevalence of anti-infective resistance underscores the urgent need for both prophylactic and therapeutic interventions.
- Despite available vaccines, vaccine-naive and immune-compromised patients remain at risk, highlighting the potential benefits of immediately available neutralizing antibodies provided by a hyperimmune globulin in both in-patient and out-patient settings.
- The ongoing post-marketing pediatric clinical study for ASCENIV may not provide label expansion opportunities.
- Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements.